Healthcare Network P&L Statement and Expansion Projects
MAX
Healthcare
Network P&L Statement: H1 FY24
Gross revenue¹
Net revenue
Direct costs
Contribution
Indirect overheads
Operating EBITDA²
Figs in INR Cr
FY21
FY22
FY23
H1 FY24
Amount
% NR
Amount
% NR
Amount
% NR
Amount
% NR
3,881
5,509
6,236
3,546
3,629
100.0%
5,218
100.0%
5,904
100.0%
3,361
100.0%
1,508
41.6%
2,103
40.3%
2,304
39.0%
1,317
39.2%
2,121
58.4%
3,115
59.7%
3,600
61.0%
2,043
60.8%
1,485
40.9%
1,725
33.1%
1,964
33.3%
1,110
33.0%
636
17.5%
1,390
26.6%
1,636
27.7%
933
27.8%
ESOP (Equity-settled scheme)
Movement in fair value of contingent consideration
payable and amortisation of contract assets³
27
0.7%
34
0.7%
34
0.6%
24
0.7%
1
0.0%
7
0.1%
4
0.1%
14
0.4%
Transaction Cost including QIP related cost & Loss on
fair valuation of pre-merger holding of Radiant under
249
6.9%
0
0.0%
Ind AS 103
Exceptional item: Payment to employees under VRS
9
0.2%
Reported EBITDA
359
9.9%
1,340
25.7%
1,597
27.1%
895
26.6%
Finance costs (net)
187
5.2%
112
2.2%
39
0.7%
(20)
(0.6%)
Depreciation and amortisation
216
6.0%
248
4.8%
260
4.4%
130
3.9%
Profit/ (Loss) before tax
(45)
(1.2%)
979
18.8%
1,298
22.0%
785
23.4%
Таха
50
1.4%
143
2.7%
(30)
(0.5%)
157
4.7%
Profit/ (Loss) after tax
(95)
(2.6%)
837
16.0%
1,328
22.5%
628
18.7%
1.
2.
Note: The numbers for the previous period have been re-casted and regrouped to make them comparable with the disclosure in the current period
FY22 includes gross revenue of INR 236 Cr from Covid-19 vaccination & related antibody tests compared to INR 2 Cr in FY23
Includes INR 85 Cr towards EBITDA from Covid-19 vaccination & related antibody tests in FY22
3.
Non cash item represents the change in fair value of contingent consideration payable to Trust/Society over the balance period (~20 to 31 years) under O&M Contracts and represents
change in the WACC, time value of discounted liability and impact of changes in future business plan projections
4.
Includes impact of one time reversal of INR 244 Cr deferred tax liability (net of capital gains tax) in FY23 pursuant to voluntary liquidation of a subsidiary
24View entire presentation